carbostyril has been researched along with Acute Symptom Flare in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barker, D; Burr, L; Dorahy, D; France, M; Greville, H; Middleton, P; Tong, K; Visser, S; Wainwright, C; Wark, P | 1 |
| Connett, GJ; Hammond, JA | 1 |
2 other study(ies) available for carbostyril and Acute Symptom Flare
| Article | Year |
|---|---|
Lumacaftor/ivacaftor reduces exacerbations in adults homozygous for Phe508del mutation with severe lung disease.
Topics: Administration, Intravenous; Adult; Aminophenols; Aminopyridines; Anti-Bacterial Agents; Australia; Benzodioxoles; Case-Control Studies; Chloride Channel Agonists; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Female; Forced Expiratory Volume; Humans; Male; Mutation; Quinolones; Respiratory Function Tests; Respiratory Tract Infections; Symptom Flare Up | 2020 |
The use of lumacaftor/ivacaftor to treat acute deterioration in paediatric cystic fibrosis.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Child; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Disease Progression; Drug Combinations; Female; Homozygote; Humans; Lung; Membrane Transport Modulators; Mutation; Patient Care Management; Quinolones; Respiratory Function Tests; Symptom Flare Up; Treatment Outcome | 2018 |